1
|
Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgués O, Rovira A, Martínez MT, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway. Int J Mol Sci 2022; 23:13292. [PMID: 36362083 PMCID: PMC9655635 DOI: 10.3390/ijms232113292] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/16/2022] [Accepted: 10/25/2022] [Indexed: 08/30/2023] Open
Abstract
Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more effective. The transcription factor SALL4 has been related to aggressiveness and resistance therapy in cancer. Its molecular mechanisms and involvement in various signaling pathways are unknown in the HER2+ breast cancer subtype. In this study, we have evaluated the implication of SALL4 in the HER2+ subtype through its expression in patients' samples and gain and loss of function in HER2+ cell lines. We found higher SALL4 expression in breast cancer tissues compared to healthy tissue. Interestingly, high SALL4 expression was associated with disease relapse and poor patient survival. In HER2+ cell lines, transient overexpression of SALL4 modulates PI3K/AKT signaling through regulating PTEN expression and BCL2, which increases cell survival and proliferation while reducing the efficacy of trastuzumab. SALL4 has also been observed to regulate the epithelial-mesenchymal transition and stemness features. SALL4 overexpression significantly reduced the epithelial markers E-cadherin, while it increased the mesenchymal markers β-catenin, vimentin and fibronectin. Furthermore, it has been also observed an increased expression of MYC, an essential transcription factor for regulating epithelial-mesenchymal transition and/or cancer stem cells. Our study demonstrates, for the first time, the importance of SALL4 in the HER2+ subtype and partial regulation of trastuzumab sensitivity. It provides a viable molecular mechanism-driven therapeutic strategy for an important subset of HER2-overexpressing patients whose malignancies are mediated by SALL4 expression.
Collapse
Affiliation(s)
| | - Ana Lameirinhas
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
| | | | - Octavio Burgués
- Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
| | - Ana Rovira
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
| | - María Teresa Martínez
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Marta Tapia
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Sandra Zazo
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Pathology, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Joan Albanell
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
- Department of Medical Oncology, Hospital del Mar, 08003 Barcelona, Spain
| | - Federico Rojo
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Pathology, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Begoña Bermejo
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Pilar Eroles
- Biomedical Research Institute INCLIVA, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Department of Physiology, Universidad de Valencia, 46010 Valencia, Spain
- Department of Biotechnology, Universidad Politécnica de Valencia, 46022 Valencia, Spain
| |
Collapse
|
2
|
Pane K, Quintavalle C, Nuzzo S, Ingenito F, Roscigno G, Affinito A, Scognamiglio I, Pattanayak B, Gallo E, Accardo A, Thomas G, Minic Z, Berezovski MV, Franzese M, Condorelli G. Comparative Proteomic Profiling of Secreted Extracellular Vesicles from Breast Fibroadenoma and Malignant Lesions: A Pilot Study. Int J Mol Sci 2022; 23:ijms23073989. [PMID: 35409352 PMCID: PMC8999736 DOI: 10.3390/ijms23073989] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 03/29/2022] [Accepted: 03/30/2022] [Indexed: 02/01/2023] Open
Abstract
Extracellular vesicles (EVs) shuttle proteins, RNA, DNA, and lipids crucial for cell-to-cell communication. Recent findings have highlighted that EVs, by virtue of their cargo, may also contribute to breast cancer (BC) growth and metastatic dissemination. Indeed, EVs are gaining great interest as non-invasive cancer biomarkers. However, little is known about the biological and physical properties of EVs from malignant BC lesions, and even less is understood about EVs from non-malignant lesions, such as breast fibroadenoma (FAD), which are clinically managed using conservative approaches. Thus, for this pilot study, we attempted to purify and explore the proteomic profiles of EVs from benign breast lesions, HER2+ BCs, triple–negative BCs (TNBCs), and continuous BC cell lines (i.e., BT-549, MCF–10A, and MDA-MB-231), combining experimental and semi-quantitative approaches. Of note, proteome-wide analyses showed 49 common proteins across EVs harvested from FAD, HER2+ BCs, TNBCs, and model BC lines. This is the first feasibility study evaluating the physicochemical composition and proteome of EVs from benign breast cells and primary and immortalized BC cells. Our preliminary results hold promise for possible implications in precision medicine for BC.
Collapse
Affiliation(s)
- Katia Pane
- IRCCS SYNLAB SDN, Via E. Gianturco 113, 80143 Naples, Italy; (K.P.); (S.N.); (E.G.)
| | - Cristina Quintavalle
- Institute for Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), Via Pansini 5, 80131 Naples, Italy;
| | - Silvia Nuzzo
- IRCCS SYNLAB SDN, Via E. Gianturco 113, 80143 Naples, Italy; (K.P.); (S.N.); (E.G.)
| | - Francesco Ingenito
- Percuros BV, Eerbeeklaan 42, 2573 HT Den Haag, The Netherlands; (F.I.); (G.R.); (A.A.)
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Via Pansini 15, 80131 Naples, Italy; (I.S.); (B.P.)
| | - Giuseppina Roscigno
- Percuros BV, Eerbeeklaan 42, 2573 HT Den Haag, The Netherlands; (F.I.); (G.R.); (A.A.)
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Via Pansini 15, 80131 Naples, Italy; (I.S.); (B.P.)
| | - Alessandra Affinito
- Percuros BV, Eerbeeklaan 42, 2573 HT Den Haag, The Netherlands; (F.I.); (G.R.); (A.A.)
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Via Pansini 15, 80131 Naples, Italy; (I.S.); (B.P.)
| | - Iolanda Scognamiglio
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Via Pansini 15, 80131 Naples, Italy; (I.S.); (B.P.)
| | - Birlipta Pattanayak
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Via Pansini 15, 80131 Naples, Italy; (I.S.); (B.P.)
| | - Enrico Gallo
- IRCCS SYNLAB SDN, Via E. Gianturco 113, 80143 Naples, Italy; (K.P.); (S.N.); (E.G.)
| | - Antonella Accardo
- Department of Pharmacy and Research Centre on Bioactive Peptides (CIRPeB), University of Naples “Federico II”, Via Mezzocannone 16, 80134 Naples, Italy;
| | - Guglielmo Thomas
- Breast Unit Clinica Mediterranea, Mediterranea Cardiocentro, Via Orazio 2, 80122 Naples, Italy;
| | - Zoran Minic
- John L. Holmes Mass Spectrometry Facility, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada; (Z.M.); (M.V.B.)
| | - Maxim V. Berezovski
- John L. Holmes Mass Spectrometry Facility, Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada; (Z.M.); (M.V.B.)
| | - Monica Franzese
- IRCCS SYNLAB SDN, Via E. Gianturco 113, 80143 Naples, Italy; (K.P.); (S.N.); (E.G.)
- Correspondence: (M.F.); (G.C.)
| | - Gerolama Condorelli
- Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Via Pansini 15, 80131 Naples, Italy; (I.S.); (B.P.)
- IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Via Atinense 18, 86077 Pozzilli, Italy
- Correspondence: (M.F.); (G.C.)
| |
Collapse
|
3
|
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Rev 2021; 41:77-105. [PMID: 34524579 PMCID: PMC8924146 DOI: 10.1007/s10555-021-09992-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Accepted: 09/02/2021] [Indexed: 12/31/2022]
Abstract
Breast cancer is the most frequent cancer in women worldwide. Despite the improvement in diagnosis and treatments, the rates of cancer relapse and resistance to therapies remain higher than desirable. Alterations in microRNAs have been linked to changes in critical processes related to cancer development and progression. Their involvement in resistance or sensitivity to breast cancer treatments has been documented by different in vivo and in vitro experiments. The most significant microRNAs implicated in modulating resistance to breast cancer therapies are summarized in this review. Resistance to therapy has been linked to cellular processes such as cell cycle, apoptosis, epithelial-to-mesenchymal transition, stemness phenotype, or receptor signaling pathways, and the role of microRNAs in their regulation has already been described. The modulation of specific microRNAs may modify treatment response and improve survival rates and cancer patients' quality of life. As a result, a greater understanding of microRNAs, their targets, and the signaling pathways through which they act is needed. This information could be useful to design new therapeutic strategies, to reduce resistance to the available treatments, and to open the door to possible new clinical approaches.
Collapse
Affiliation(s)
| | | | | | - Ana Lameirinhas
- INCLIVA Biomedical Research Institute, 46010, Valencia, Spain
| | | | - Eduardo Tormo
- INCLIVA Biomedical Research Institute, 46010, Valencia, Spain.,Center for Biomedical Network Research On Cancer, CIBERONC-ISCIII, 28029, Madrid, Spain
| | | | - Pilar Eroles
- INCLIVA Biomedical Research Institute, 46010, Valencia, Spain. .,Center for Biomedical Network Research On Cancer, CIBERONC-ISCIII, 28029, Madrid, Spain. .,Department of Physiology, University of Valencia, 46010, Valencia, Spain.
| |
Collapse
|
4
|
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Pattanayak B, Tormo E, Miranda-Gonçalves VM, Macedo-Silva C, Rojo F, Zazo S, Madoz-Gúrpide J, Burgues O, Hernando C, Martínez M, Moragón S, Bermejo De Las Heras B, Lluch A, Jerónimo C, Eroles P, Cejalvo JM. miR-503-5p induces doxorubicin resistance in triple-negative breast cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.1083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1083 Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer (BC) subtype comprising approximately 15% of BC. Conventional cytotoxic chemotherapies continue to be the mainstay for treatment of this BC, which lacks targetable markers. In this context, microRNAs have been described to have an important role. The aim of this work was to elucidate the function of miR-503-5p in doxorubicin resistance in TNBC. Methods: miR-503-5p expression was evaluated in the TNBC cell line with acquired resistance to doxorubicin (MDA-MB-231R) and its parental cell line (MDA-MB-231), by qRT-PCR. Studies of gain/loss of function of miR-503-5p were carried out in MDA-MB-231 and MDA-MB-231R cells by transient transfection of mimics and inhibitors. Cells were treated with doxorubicin, and viability was measured by flow cytometry and MTT assay. The role of miR-503-5p was also evaluated in vivo by Chicken Chorioallantoic Membrane (CAM) assay. MDA-MB-231 cells transfected with miR-503-5p mimic or scramble miRNA were inoculated onto the CAM of fertilized chicken eggs. After 48 hours, tumours were treated with doxorubicin or supplemented media for 48 hours and tumour growth was measured. miR-503-5p expression was quantified by qRT-PCR in a retrospective cohort of 74 TNBC patients treated with anthracycline + taxane regimens. Overall survival analysis for miR-503-5p in TNBC patients from METABRIC dataset was evaluated by the KM plotter online tool. Results: miR-503-5p was significantly upregulated in the resistant MDA-MB-231R TNBC cell line when compared to its parental cell line MDA-MB-231 (̃3.5-fold; p< 0.0001). Then, gain/loss function assays showed that upregulation of miR-503-5p in MDA-MB-231 cells increased resistance to doxorubicin ( p< 0.0001) and its downregulation in MDA-MB-231R cells had the opposite effect ( p< 0.0001). Moreover, the role of miR-503-5p was also confirmed in the CAM assay in vivo model, where miR-503-5p overexpression inhibited the effect of doxorubicin. In our cohort of patients, miR-503-5p expression levels in core biopsies sampled before preoperative chemotherapy were associated with residual cancer burden (RCB). miR-503-5p expression was significantly higher in patients with poor response to chemotherapy (RCB II and III; median, 95% CI: 0.00055, 0.00024 - 0.00136) than in patients with good response (RCB 0 and I; median, 95% CI: 0.00018, 0.00011 - 0.00034; p = 0.036). Moreover, we confirmed that TNBC patients with high expression of miR-503-5p had worse overall survival than patients with low expression ( p= 0.016). Conclusions: We identified miR-503-5p as a modulator of doxorubicin resistance in TNBC. Our in vitro findings are supported by the clinical data of TNBC patients and in vivo assays. Hence, the inhibition of miR-503-5p may be a promising strategy to improve chemotherapeutic efficacy. Moreover, the expression levels of miR-503-5p may be used as a biomarker for therapy response in TNBC.
Collapse
Affiliation(s)
| | | | | | | | - Eduardo Tormo
- Institute of Health Research (INCLIVA), Valencia, Spain
| | - Vera Mónica Miranda-Gonçalves
- Cancer Biology and Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal
| | - Catarina Macedo-Silva
- Cancer Biology and Epigenetics Group-Research Center, Portuguese Oncology Institute of Porto (CI-IPOP), Porto, Portugal
| | - Federico Rojo
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Sandra Zazo
- Translational Oncology Division, Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain
| | | | - Octavio Burgues
- Department of Pathology. Hospital Clinico Universitario de Valencia, Valencia, Spain
| | - Cristina Hernando
- Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain
| | - Maite Martínez
- Hospital Clinico Universitario de Valencia, Incliva, Valencia, Spain
| | - Santi Moragón
- Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - Begoña Bermejo De Las Heras
- Hospital Clinico Universitario de Valencia, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Valencia, Spain
| | - Carmen Jerónimo
- Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
| | - Pilar Eroles
- Institute of Health Research (INCLIVA), Valencia, Spain
| | - Juan Miguel Cejalvo
- Hospital Clínico Universitario de Valencia, Biomedical Research Institute INCLIVA, Valencia, Spain
| |
Collapse
|
5
|
Pattanayak B, Garrido-Cano I, Adam-Artigues A, Tormo E, Pineda B, Cabello P, Alonso E, Bermejo B, Hernando C, Martínez MT, Rovira A, Albanell J, Rojo F, Burgués O, Cejalvo JM, Lluch A, Eroles P. MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma. Front Oncol 2020; 10:1661. [PMID: 33014831 PMCID: PMC7511588 DOI: 10.3389/fonc.2020.01661] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Accepted: 07/28/2020] [Indexed: 12/11/2022] Open
Abstract
Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients’ samples. The upregulation of miR-33b suppressed proliferation, induced apoptosis, reduced invasion, migration and regulated EMT by an increase of E-cadherin and a decrease of ß-catenin and vimentin. The silencing of EZH2 mimicked the impact of miR-33b overexpression. Furthermore, the inhibition of miR-33b induces cell proliferation, invasion, migration, EMT, and EZH2 expression in non-tumorigenic cells. Importantly, the Kaplan–Meier analysis showed a significant association between high miR-33b expression and better overall survival. These results suggest miR-33b as a suppressive miRNA that could inhibit tumor metastasis and invasion in HER2+ BC partly by impeding EMT through the repression of the MYC–EZH2 loop.
Collapse
Affiliation(s)
| | | | | | - Eduardo Tormo
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain
| | - Begoña Pineda
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Physiology, University of Valencia, Valencia, Spain
| | - Paula Cabello
- Biomedical Research Institute, INCLIVA, Valencia, Spain
| | - Elisa Alonso
- Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Pathology, Hospital Clinico de Valencia, Valencia, Spain
| | - Begoña Bermejo
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Cristina Hernando
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - María Teresa Martínez
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Ana Rovira
- Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.,Department of Medical Oncology, Hospital del Mar, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain
| | - Joan Albanell
- Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.,Department of Medical Oncology, Hospital del Mar, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain.,Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Federico Rojo
- Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Pathology, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain
| | - Octavio Burgués
- Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Pathology, Hospital Clinico de Valencia, Valencia, Spain
| | - Juan Miguel Cejalvo
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Ana Lluch
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,Department of Physiology, University of Valencia, Valencia, Spain.,Department of Oncology, Hospital Clinico de Valencia, Valencia, Spain
| | - Pilar Eroles
- Biomedical Research Institute, INCLIVA, Valencia, Spain.,Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III Madrid, Spain.,COST action CA15204, Brussels, Belgium
| |
Collapse
|
6
|
Aguado EO, Martinez M, Carbonell-Asins J, Montón-Bueno J, Ortega B, Poveda J, Tapia M, Moragón S, Melia CH, Candia L, Simon S, Adam-Artigues A, Garrido-Cano I, Pattanayak B, Tormo E, Eroles P, Lluch A, De Las Heras BB, Cejalvo J. 319P Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
7
|
Tormo Martin E, Adam-Artigues A, Garrido-Cano I, Pineda Merlo B, Pattanayak B, Cabello P, Albanell J, Rojo F, Lluch A, Eroles P. Role of miR-449 family on doxorubicin-based chemotherapy response in triple-negative breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
8
|
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Cabello P, Pineda B, Tormo E, Albanell J, Rojo F, Lluch A, Eroles P. Involvement of miR-99a in resistance to chemotherapy in triple-negative breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Pattanayak B, Herrera G, Garrido-Cano I, Adam-Artigues A, Tormo E, Pineda Merlo B, Cabello P, Lluch A, Eroles P. Characterization of the different cell population in primary culture of breast tumor. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy318.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Adam Artigues A, Tormo E, Cerro-Herreros E, Sabater M, Garrido-Cano I, Pineda Merlo B, Pattanayak B, Cabello P, Artero R, Eroles P. Muscleblind-like 1 regulates epithelial to mesenchymal transition markers in triple-negative breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Cabello P, Forés J, Tormo E, Pineda B, Adam A, Garrido I, Pattanayak B, Lluch A, Eroles P. Involvement of microRNA-146a in trastuzumab resistance of HER2+ breast cancer cells. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx513.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Pattanayak B, Adam-Artigues A, Tormo E, Garrido I, Pineda B, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P. Micro-RNA 33b inhibits breast cancer migration and invasion through regulating epithelial-mesenchymal transition in HER2 positive breast cancer cell lines. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx511.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|